ctDNA Methylation for Epithelial Ovarian Cancer

Launched by LEI LI · Mar 24, 2023

Keywords

ClinConnect Summary

This clinical trial, called the OVAMethy study, is focused on finding a better way to diagnose and monitor epithelial ovarian cancer, which is a serious type of cancer in women. Researchers want to see if changes in certain genes found in the blood can help detect ovarian cancer early and predict how well patients will do. They have already found that specific genes are altered in ovarian cancer, and they believe that measuring these changes in blood samples could give them valuable information about the disease.

To participate in this study, you must be a female aged 18 or older who is not currently receiving any cancer treatment and has a confirmed diagnosis related to ovarian issues. If you choose to join, you will undergo blood tests and possibly other examinations to help researchers understand how effective this new method is compared to traditional tests. The trial is currently recruiting participants across more than ten research centers and aims to include over 5,000 women. Your involvement could contribute to important advancements in the early detection and treatment of ovarian cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Outpatient routine follow-up population
• • Age is greater than or equal to 18 years
• • Not receiving any chemotherapy, physical therapy, or surgical treatment for ovarian lesions
• • Wtih pathological ovarian results
• • Willing to be tested and signed an informed consent form
• • With available data of plasma CA125, Human epididymis protein 4 and effective imaging results
• Exclusion Criteria:
• • Not meeting all the including criteria
• • WithoutoOvarian pathology or surgical pathology information could not be obtained
• • A sample of patients withdrawing from the trial
• • Samples that the investigator believes should be excluded from this trial